Companies: 10,795·Total market cap: $144.5T
Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited

TAKNYSEHealthcare● Active
$15.74
+$0.14(+0.90%)
Market Cap$49.7B
P/E Ratio
52W High$18.9
52W Low$12.99
Overview

Takeda Pharmaceutical Company Limited (TAK) Shares Outstanding — Overview

Basic and diluted weighted average shares, YoY change, float context, and historical trend from SEC filings and FMP.

TAK · shares outstanding · updated Jun 10, 2026

Key metrics

Basic Shares Outstanding · Weighted average · fiscal year
3.150B -1.89% YoY Change
FY · as of Mar 31, 2026 · Reported in JPY
vs 3.211B in FY 2025
Diluted Shares Outstanding
3.206B
incl. options, RSUs, convertibles
Dilution Spread
+1.76%
Diluted vs Basic
YoY Change
-1.89%
year-over-year
Float (Free Float)
3.160B
publicly tradable shares
100.0% of total
Source: FMP /income-statement · /shares-float · SEC 10-K / 10-QUpdated: 2026-06-10

Shares Outstanding Growth Rate

3-Year CAGRincreasing
+0.5%
2023 → 2026
5-Year CAGRincreasing
+0.2%
2021 → 2026
10-Year CAGRincreasing
+7.2%
2016 → 2026

Negative CAGR typically indicates share buyback or retirement activity. Interpret alongside Splits and Financials tabs. Splits / Financials

Shares outstanding history

↓ Decrease — typically buyback / retirement
↑ Increase — issuance / equity compensation
Latest
* most recent reported · FMP /income-statement · weightedAverageShsOut

Annual shares outstanding by year

FY 2026Latest
Diluted Shares: 3.206B
3.150B
-1.89%
FY 2025
Diluted Shares: 3.211B
3.211B
+2.61%
FY 2024
Diluted Shares: 3.161B
3.129B
+0.81%
FY 2023
Diluted Shares: 3.140B
3.104B
-0.75%
FY 2022
Diluted Shares: 3.154B
3.127B
+0.10%
FMP /income-statement · weightedAverageShsOut · weightedAverageShsOutDilUnit: Billions (B)

Healthcare sector shares outstanding comparison

Shares Outstanding for similar companies or competitors in the Healthcare sector.

#SymbolCompanyShares (Basic)vs TAK
#1
Takeda Pharmaceutical Company LimitedTAK
Takeda Pharmaceutical Company LimitedYOU
3.150B
#2
Merck & Co., Inc.MRK
Merck & Co., Inc.
2.502B-20.6%
#3
Johnson & JohnsonJNJ
Johnson & Johnson
2.429B-22.9%
#4
AbbVie Inc.ABBV
AbbVie Inc.
1.780B-43.5%
#5
AstraZeneca PLCAZN
AstraZeneca PLC
1.550B-50.8%
#6
UnitedHealth Group IncorporatedUNH
UnitedHealth Group Incorporated
910.0M-71.1%
#7
Eli Lilly and CompanyLLY
Eli Lilly and Company
898.0M-71.5%

/company-screener · per-peer /income-statement · cache 86400s

Understanding Shares Outstanding

What Are Shares Outstanding? (Basic)

Takeda Pharmaceutical Company Limited (TAK) shares outstanding is the total number of issued shares held by shareholders — the basis for Basic EPS and market capitalization. As of March 31, 2026, Takeda Pharmaceutical Company Limited reports 3.150B basic shares outstanding (weighted average).

Basic vs. Diluted Shares Outstanding

Takeda Pharmaceutical Company Limited's basic shares outstanding (3.150B) represents currently issued shares. Diluted shares outstanding (3.206B) also includes potential shares from stock options, RSUs, and convertibles. Dilution spread: +1.76%.

Shares Outstanding vs. Float (Free Float)

Takeda Pharmaceutical Company Limited's float is 3.160B (100.0% of total shares outstanding) — shares freely available for public trading, excluding insider-held and restricted shares.

Float3.160B(100.0%)
Outstanding3.160B

Float data from /shares-float reflects the most recent SEC filing period-end. The weighted average shares (from /income-statement) may differ — this is a normal reporting window difference, not a data error.

FMP /income-statement · /shares-float · SEC EDGAR · JPY

About shares outstanding & methodology

Takeda Pharmaceutical Company Limited (TAK) shares outstanding history from 2007 to 2026. Shares outstanding can be defined as the total number of shares held by all shareholders — including institutional investors, retail investors, and company insiders — assuming conversion of all convertible debt, securities, warrants, and options. This metric excludes the company's treasury shares.

Takeda Pharmaceutical Company Limited shares outstanding for the fiscal year ending March 31, 2026 were 3.150B, a 1.89% decline year-over-year. Takeda Pharmaceutical Company Limited FY 2026 shares outstanding were 3.150B, a -1.89% decline from FY 2025.

Takeda Pharmaceutical Company Limited is a leading company operating in the Healthcare sector. The company's share count trajectory — with a 10-year CAGR of +7.2% — is a key signal for investors evaluating capital return policy, EPS accretion, and long-term shareholder value creation.

Figures tie to SEC 10-K/10-Q income statement disclosures and FMP /income-statement · /shares-float where noted.

Frequently asked questions

TAK shares outstanding · 4 questions

As of March 31, 2026, Takeda Pharmaceutical Company Limited (TAK) has approximately 3.150B basic shares outstanding and 3.206B diluted shares outstanding. This represents a -1.89% year-over-year change from FY 2025 (3.211B). Takeda Pharmaceutical Company Limited's declining share count is primarily driven by its share buyback program. For the complete historical data table, see the history table above.

TAK shares outstandinghow many shares does TAK haveTAK basic shares 2026TAK diluted shares

Data: FMP /income-statement · /shares-float · SEC EDGAR · weighted average basis · Takeda Pharmaceutical Company Limited SEC 10-K & 10-Q filings · US GAAP · Last updated: 2026-06-10